

Ruwanthi Kolamunnage-Dona

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9041877/publications.pdf>

Version: 2024-02-01

58
papers

2,066
citations

304743

22
h-index

254184

43
g-index

63
all docs

63
docs citations

63
times ranked

3676
citing authors

#	ARTICLE	IF	CITATIONS
1	External validation and recalibration of an incidental meningioma prognostic model â€œ IMPACT: protocol for an international multicentre retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e052705.	1.9	6
2	Cardiovascular drugs and COVIDâ€19 clinical outcomes: a systematic review and metaâ€analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3577-3599.	2.4	7
3	Adjustment for the measurement error in evaluating biomarker performances at baseline for future survival outcomes: Time-dependent receiver operating characteristic curve within a joint modelling framework. <i>Research Methods in Medicine & Health Sciences</i> , 2021, 2, 51-60.	1.2	0
4	Procalcitonin, C-reactive protein, neutrophil gelatinase-associated lipocalin, resistin and the APTT waveform for the early diagnosis of serious bacterial infection and prediction of outcome in critically ill children. <i>PLoS ONE</i> , 2021, 16, e0246027.	2.5	6
5	Cardiovascular drugs and COVIDâ€19 clinical outcomes: A living systematic review and metaâ€analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4534-4545.	2.4	16
6	Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 75, 879-887.	3.7	12
7	TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2020, 70, 2062-2072.	5.8	10
8	Spatial and spatio-temporal statistical analyses of retinal images: a review of methods and applications. <i>BMJ Open Ophthalmology</i> , 2020, 5, e000479.	1.6	1
9	Faster Monte Carlo estimation of joint models for time-to-event and multivariate longitudinal data. <i>Computational Statistics and Data Analysis</i> , 2020, 151, 107010.	1.2	14
10	Spatial Linear Mixed Effects Modelling for OCT Images: SLME Model. <i>Journal of Imaging</i> , 2020, 6, 44.	3.0	2
11	A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas. <i>Neuro-Oncology</i> , 2020, 22, 278-289.	1.2	56
12	Clinical studies of incidental intracranial meningiomasâ€towards high-quality evidence-based practice. <i>Acta Neurochirurgica</i> , 2020, 162, 673-674.	1.7	2
13	Bayesian joint modelling of longitudinal and time to event data: a methodological review. <i>BMC Medical Research Methodology</i> , 2020, 20, 94.	3.1	23
14	Treatment Outcomes of Incidental Intracranial Meningiomas: Results from the IMPACT Cohort. <i>World Neurosurgery</i> , 2020, 138, e725-e735.	1.3	19
15	Investigation of oneâ€stage metaâ€analysis methods for joint longitudinal and timeâ€toâ€event data through simulation and real data application. <i>Statistics in Medicine</i> , 2019, 38, 247-268.	1.6	5
16	Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by <i>Talaromyces marneffei</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	6
17	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-140.	2.8	18
18	Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. <i>Efficacy and Mechanism Evaluation</i> , 2019, 6, 1-168.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Joint Models of Longitudinal and Time-to-Event Data with More Than One Event Time Outcome: A Review. <i>International Journal of Biostatistics</i> , 2018, 14, .	0.7	23
20	Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by <i>Aspergillus flavus</i> . <i>Journal of Infectious Diseases</i> , 2018, 217, 1118-1127.	4.0	47
21	Investigation of 2-stage meta-analysis methods for joint longitudinal and time-to-event data through simulation and real data application. <i>Statistics in Medicine</i> , 2018, 37, 1227-1244.	1.6	4
22	A Comparison of Joint Models for Longitudinal and Competing Risks Data, with Application to an Epilepsy Drug Randomized Controlled Trial. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2018, 181, 1105-1123.	1.1	22
23	Statistical primer: performing repeated-measures analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 26, 539-544.	1.1	19
24	Time-dependent efficacy of longitudinal biomarker for clinical endpoint. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1909-1924.	1.5	6
25	MNGI-22. A PROGNOSTIC INDEX TO PREDICT THE RISK OF ACTIVE MONITORING FAILURE FOR INCIDENTALLY-FOUND ASYMPTOMATIC MENINGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi153-vi153.	1.2	0
26	Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	12
27	joineRML: a joint model and software package for time-to-event and multivariate longitudinal outcomes. <i>BMC Medical Research Methodology</i> , 2018, 18, 50.	3.1	42
28	Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	5
29	Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. <i>Clinical Infectious Diseases</i> , 2017, 64, 1557-1563.	5.8	39
30	Time-dependent ROC curve analysis in medical research: current methods and applications. <i>BMC Medical Research Methodology</i> , 2017, 17, 53.	3.1	503
31	Predicting Risk of Serious Bacterial Infections in Febrile Children in the Emergency Department. <i>Pediatrics</i> , 2017, 140, .	2.1	54
32	Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. <i>Journal of Personalized Medicine</i> , 2017, 7, 19.	2.5	2
33	Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. <i>Journal of Personalized Medicine</i> , 2017, 7, 1.	2.5	41
34	Pharmacodynamics of the Orotomides against <i>Aspergillus fumigatus</i> : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. <i>MBio</i> , 2017, 8, .	4.1	47
35	A Randomized Controlled Trial of Extended Brief Intervention for Alcohol-Dependent Patients in an Acute Hospital Setting. <i>Alcohol and Alcoholism</i> , 2016, 51, 584-592.	1.6	3
36	Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues. <i>BMC Medical Research Methodology</i> , 2016, 16, 117.	3.1	112

#	ARTICLE	IF	CITATIONS
37	Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis. <i>BMC Medical Research Methodology</i> , 2016, 16, 168.	3.1	37
38	Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study. <i>Trials</i> , 2016, 17, 222.	1.6	6
39	Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. <i>PLoS ONE</i> , 2016, 11, e0149803.	2.5	75
40	Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. <i>BMJ Open</i> , 2015, 5, e009566.	1.9	9
41	Evaluating statistical characteristics of biomarker-guided trial designs. <i>Trials</i> , 2015, 16, .	1.6	0
42	Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium difficile Infection (CDI): A Prospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e106118.	2.5	39
43	ECONOMIC EVALUATION OF NEBULIZED MAGNESIUM SULPHATE IN ACUTE SEVERE ASTHMA IN CHILDREN. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 354-360.	0.5	7
44	Is the Interleukin 8 Promoter Polymorphism rs4073/-251T >A Associated With Clostridium difficile Infection?. <i>Clinical Infectious Diseases</i> , 2014, 58, e148-e151.	5.8	6
45	Serum Mannose-Binding Lectin Concentration, but Not Genotype, Is Associated With Clostridium difficile Infection Recurrence: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 59, 1429-1436.	5.8	15
46	A review of the handling of missing longitudinal outcome data in clinical trials. <i>Trials</i> , 2014, 15, 237.	1.6	64
47	Assessment and clinical course of hypocalcemia in critical illness. <i>Critical Care</i> , 2013, 17, R106.	5.8	97
48	A multistate modelling approach for pancreatic cancer development in genetically high-risk families. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2013, 62, 201-212.	1.0	2
49	Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2013, 1, 301-308.	10.7	64
50	Novel biomarker combination improves the diagnosis of serious bacterial infections in Malawian children. <i>BMC Medical Genomics</i> , 2012, 5, 13.	1.5	17
51	Depressive and manic symptoms are not opposite poles in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 206-210.	4.5	37
52	A randomised controlled trial of extended brief intervention for alcohol dependent patients in an acute hospital setting (ADPAC). <i>BMC Public Health</i> , 2011, 11, 528.	2.9	10
53	Brief Interventions in Dependent Drinkers: A Comparative Prospective Analysis in Two Hospitals. <i>Alcohol and Alcoholism</i> , 2011, 46, 434-440.	1.6	26
54	Enhanced relapse prevention for bipolar disorder by community mental health teams: cluster feasibility randomised trial. <i>British Journal of Psychiatry</i> , 2010, 196, 59-63.	2.8	52

#	ARTICLE	IF	CITATIONS
55	Assessing the potential for outcome reporting bias in a review: a tutorial. <i>Trials</i> , 2010, 11, 52.	1.6	54
56	Patients with epilepsy: Cognitively compromised before the start of antiepileptic drug treatment?. <i>Epilepsia</i> , 2010, 51, 48-56.	5.1	157
57	Joint modelling of longitudinal and competing risks data. <i>Statistics in Medicine</i> , 2008, 27, 6426-6438.	1.6	69
58	The influence of competing-risks setting on the choice of hypothesis test for treatment effect. <i>Biostatistics</i> , 2007, 8, 689-694.	1.5	34